Attached files

file filename
EX-99.1 - EX-99.1 - THERAVANCE INCa10-10395_2ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 


 

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported):  May 19, 2010

 


 

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

 


 

Delaware

 

000-30319

 

94-3265960

(State or Other Jurisdiction of

Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification Number)

 

901 Gateway Boulevard

South San Francisco, California 94080

(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 8.01 Other Events.

 

Today at the American Thoracic Society International Conference in New Orleans, Louisiana, GlaxoSmithKline (GSK) presented a poster containing information from a Phase 2a study with vilanterol trifenatate (GW642444), the long-acting beta2 agonist (LABA) in RELOVAIR™.  RELOVAIR™ is a next-generation, once-daily combination medicine of vilanterol trifenatate and an inhaled corticosteroid, fluticasone furoate, being developed for the treatment of patients with chronic obstructive pulmonary disorder or asthma.  RELOVAIR™ is being developed under the LABA collaboration with GSK and Theravance, Inc. The poster is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)              Exhibits

 

Exhibit

 

Description

 

 

 

Exhibit 99.1

 

Vilanterol trifenatate (VI; GW642444M), a novel inhaled long-acting beta2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100mcg, is well tolerated and demonstrates prolonged bronchodilation in asthmatic patients

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

THERAVANCE, INC.

 

 

Date: May 19, 2010

By:

/s/ Michael W. Aguiar

 

 

 

 

 

Michael W. Aguiar

 

 

Chief Financial Officer

 

3



 

EXHIBIT INDEX

 

Exhibit

 

Description

 

 

 

Exhibit 99.1

 

Vilanterol trifenatate (VI; GW642444M), a novel inhaled long-acting beta2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100mcg, is well tolerated and demonstrates prolonged bronchodilation in asthmatic patients

 

4